Literature DB >> 12901237

BAY-43-9006 Bayer/Onyx.

John T Lee1, James A McCubrey.   

Abstract

Bayer and Onyx are developing BAY-43-9006, an oral cytostatic Raf kinase inhibitor for the potential treatment of colorectal and breast cancers, hepatocellular carcinoma and non-small-cell lung cancer, in addition to acute myelogenous leukemia, myelodysplastic syndrome and other cancers. A US IND was filed in May 2000 and by February 2003 BAY-43-9006 was in phase II trials, with phase III trials expected to begin later in 2003.

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 12901237

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  12 in total

Review 1.  Molecular genesis of non-muscle-invasive urothelial carcinoma (NMIUC).

Authors:  Courtney Pollard; Steven C Smith; Dan Theodorescu
Journal:  Expert Rev Mol Med       Date:  2010-03-25       Impact factor: 5.600

Review 2.  Selective Raf inhibition in cancer therapy.

Authors:  Vladimir Khazak; Igor Astsaturov; Ilya G Serebriiskii; Erica A Golemis
Journal:  Expert Opin Ther Targets       Date:  2007-12       Impact factor: 6.902

3.  A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer.

Authors:  A Dasari; L Gore; W A Messersmith; S Diab; A Jimeno; C D Weekes; K D Lewis; H A Drabkin; T W Flaig; D R Camidge
Journal:  Invest New Drugs       Date:  2012-03-14       Impact factor: 3.850

4.  Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib.

Authors:  Lucia Jilaveanu; Christopher Zito; Sandra J Lee; Katherine L Nathanson; Robert L Camp; David L Rimm; Keith T Flaherty; Harriet M Kluger
Journal:  Clin Cancer Res       Date:  2009-02-01       Impact factor: 12.531

5.  Identifying drug effects via pathway alterations using an integer linear programming optimization formulation on phosphoproteomic data.

Authors:  Alexander Mitsos; Ioannis N Melas; Paraskeuas Siminelakis; Aikaterini D Chairakaki; Julio Saez-Rodriguez; Leonidas G Alexopoulos
Journal:  PLoS Comput Biol       Date:  2009-12-04       Impact factor: 4.475

6.  Genetic and functional characterization of putative Ras/Raf interaction inhibitors in C. elegans and mammalian cells.

Authors:  Vanessa González-Pérez; David J Reiner; Jamie K Alan; Cicely Mitchell; Lloyd J Edwards; Vladimir Khazak; Channing J Der; Adrienne D Cox
Journal:  J Mol Signal       Date:  2010-02-23

Review 7.  Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials.

Authors:  Margaret E Macy; Kelly K Sawczyn; Timothy P Garrington; Douglas K Graham; Lia Gore
Journal:  Curr Oncol Rep       Date:  2008-11       Impact factor: 5.075

Review 8.  Synergistic combinations of signaling pathway inhibitors: mechanisms for improved cancer therapy.

Authors:  Paul Dent; David T Curiel; Paul B Fisher; Steven Grant
Journal:  Drug Resist Updat       Date:  2009-04-22       Impact factor: 18.500

9.  Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.

Authors:  Anna Tesei; Carlo Leonetti; Gabriella Zupi; Marco Scarsella; Giovanni Brigliadori; Paola Ulivi; Francesco Fabbri; Chiara Arienti; Dino Amadori; Alessandro Passardi; Rosella Silvestrini; Wainer Zoli
Journal:  J Cell Mol Med       Date:  2011-02       Impact factor: 5.310

10.  Genetic targeting of B-RafV600E affects survival and proliferation and identifies selective agents against BRAF-mutant colorectal cancer cells.

Authors:  Benjamin Hirschi; Eike Gallmeier; Andreas Ziesch; Maximilian Marschall; Frank T Kolligs
Journal:  Mol Cancer       Date:  2014-05-24       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.